Piper Sandler analyst David Westenberg reiterated a Buy rating on Cytek Biosciences (CTKB – Research Report) today and set a price target of $15.00. The company’s shares closed last Friday at $9.39.
Westenberg covers the Healthcare sector, focusing on stocks such as Zoetis, Natera, and Guardant Health. According to TipRanks, Westenberg has an average return of 0.6% and a 46.55% success rate on recommended stocks.
Currently, the analyst consensus on Cytek Biosciences is a Moderate Buy with an average price target of $14.00.
See today’s best-performing stocks on TipRanks >>
CTKB market cap is currently $1.28B and has a P/E ratio of -211.49.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells.
Read More on CTKB:
- Cytek Biosciences to Participate in the UBS MedTech, Tools and Genomics Summit
- Cytek Biosciences reports Q2 EPS (3c), consensus 3c
- Cytek Biosciences to Report Second Quarter 2023 Financial Results on August 8, 2023
- Raymond James starts Cytek with a Market Perform as budgets tighten
- Cytek Biosciences initiated with a Market Perform at Raymond James
